As­traZeneca of­floads for­mer crown jew­el Crestor as it con­tin­ues to re­fo­cus on on­col­o­gy drugs

This is the way Crestor ends. Not with a bang, but a whim­per.

As­traZeneca is sell­ing off Eu­ro­pean rights for the once mighty megablock­buster to the Ger­man firm Grü­nen­thal for $320 mil­lion up­front, the Big Phar­ma said Tues­day, as it bids farewell to one of its for­mer rev­enue dri­vers. The price paid is a far cry from peak sales in 2011 of more than $6.6 bil­lion and $5 bil­lion in sales as re­cent­ly as 2015.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.